CIRIUM
1.9.2022 10:01:34 CEST | Business Wire | Press release
The major US carriers made a clean sweep of the top four places as aviation analytics firm Cirium revealed its World Airline Passenger Rankings for 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005886/en/
US majors take top spot while low-cost carriers rise up the Cirium global airlines rankings. (Graphic: Business Wire)
American Airlines stays on top of the ranking again in 2021, followed by Delta Air Lines, United Airlines and Southwest Airlines, demonstrating the strength of the recovery that continues to take place in the US domestic market.
Overall, airlines in North America showed 75% growth from the low point in 2020, although still ending last year down by 40% on 2019 traffic levels, as measured in Revenue Passenger Kilometers/Miles (RPKs/RPMs).
The ranking, which is based on over 600 operators tracked in the Cirium airline database, shows that world traffic ended 2021 down by 57% against the pre-pandemic peak. In terms of passenger numbers, the total stood at 2.3 billion for the year, representing around half of the volumes from the peak in 2019.
Low-cost carriers continued to rise up the rankings across the regions. Ryanair cemented its place as Europe’s largest carrier, sitting in fifth place just below Southwest, and was the only European airline to make it into the top 10.
Europe’s major network carriers have fared less well over the past couple of years, as demand for long-haul, premium travel remained depressed. Although Air France held steady at 13th place, Lufthansa slipped down the rankings and British Airways fell out of the top 20 altogether. Virgin Atlantic also dropped more than 50 places as it too suffered from the slow return of long-haul and premium traffic.
The big three carriers in mainland China – China Southern, China Eastern and Air China – held their place toward the top of the ranking, although that could change after a renewed round of COVID-19 lockdowns in Chinese cities so far this year.
Across Asia Pacific as a whole – in stark contrast to recovery in all other world regions – airlines saw traffic fall again last year. Cathay Pacific slipped spectacularly, falling out of the top 100 ranking entirely following Hong-Kong’s pursuit of an aggressive zero-COVID strategy. It was not alone. Carriers across the region in Indonesia, Malaysia, South Korea and Thailand also continued to shrink.
In Japan, All Nippon Airways and Japan Airlines had lost nearly 85% of their traffic in 2020 and were still down by around 75% by the end of 2021. Both fell steeply down the rankings as a result.
Jeremy Bowen, Cirium CEO, said: “Pre-pandemic, Asia Pacific airlines held the single largest share of global passenger traffic, with over a third of the world total. By 2021 the region was overtaken by North America, led by the strong recovery in domestic US flying.”
Two Gulf carriers, Emirates and Qatar Airways, both retained their position within the top 10 airlines, although the gap between them narrowed. Emirates slipped four places to sit just ahead of a rising Qatar Airways, which has made a point of maintaining as much of its network as possible.
Turkish Airlines, helped by an extensive domestic market free of cross-border travel restrictions, climbed four places to 10th in the latest ranking compared with 2019.
The Cirium ranking highlights the struggle which mainline carriers have faced, especially those relying on a strong mix of business travel and long-haul flying. By 2021 their share of world passenger traffic had slipped some five percentage points to 64%. That decline was largely picked up by low-cost carriers, who raised their share to 26%.
Cirium’s World Airline Passenger Ranking 2021 is a premium analysis available in Cirium Dashboard. The report features:
- The Top 200 airlines by passenger traffic
- The Top 50 airline groups by passenger traffic
- The Top 50 airlines by passenger volume
- Passenger traffic by region and by airline type 2019-2021
- Share of passenger traffic by airline region and airline type
- Share of passenger volume by airline type
Click here to download the full report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
